Scholars Central

Conference abstractPublished 19 Mar 2018

Induction of tolerance to allogeneic islet grafts using an immunomodulatory biomaterial

Authors: Haval Shirwan

University of Louisville, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Type 1 diabetes (T1D) is a chronic autoimmune disease that impacts millions of people world-wide. Presently, there is no cure for T1D and treatment with exogenous insulin to manage diabetes is ineffective in controlling euglycemia in a substantial population of type 1 diabetics. Transplantation of pancreatic islets as a source of beta cells producing insulin has proven effective in improving metabolic control in type 1 diabetic individuals. However, graft rejection is a major limitation of clinical islet transplantation that is controlled by chronic immunosuppression. Systemic use of immunosuppression is associated with various adverse effects that compromises the life quality of graft recipients. We have been pursuing the development of targeted and localized immunomodulatory approaches as a safe and effective alternative to chronic immunosuppression. In particular, we developed biomaterials based on polyethylene glycol microparticles engineered with immunomodulatory ligands targeting islet destructive pathogenic T effector cells for physical elimination within the graft microenvironment. The application of this novel concept to the induction of tolerance to islet allografts as a cure for T1D will be discussed.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectImmunology & Microbiology
  • SubjectMaterials Science
  • BylineArticles whose byline prints “Haval Shirwan”